ISUPREL
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
May 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ISUPREL is an injectable sympathomimetic amine approved in 1956, representing a legacy cardiovascular and respiratory therapeutic. The exact mechanism of action and indications are not specified in available data, but historical use suggests beta-adrenergic agonist activity. This is an established NDA product with approaching loss of exclusivity.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100) signals a contracting team focus on retention and cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ISUPREL currently has zero linked job openings, reflecting its mature, low-growth status. Career opportunities center on defensive portfolio management, generic transition planning, and operational cost control rather than innovation or expansion.
Senior Brand ManagerMedical Science Liaison
Worked on ISUPREL at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.